What are the indications, dosing schedule, administration route, contraindications, and safety profile of Influvac (inactivated split‑virion influenza vaccine) for individuals aged 6 months and older, including pregnant women?

Influvac Vaccine: Clinical Overview

Indications

Influvac is indicated for annual influenza prophylaxis in all individuals aged ≥6 months, including pregnant women, with no upper age limit. 1, 2, 3, 4

• Universal vaccination is recommended for all persons ≥6 months who do not have contraindications, regardless of risk status 2, 3, 4
• Priority groups requiring special outreach include:
  • Children aged 6 months through 8 years (especially those <2 years who have higher hospitalization rates) 1, 5, 6
  • Adults ≥50 years 1
  • Pregnant women at any stage of pregnancy 2, 5, 7
  • Persons with chronic medical conditions (asthma, diabetes, cardiovascular disease, immunosuppression, neurologic disorders) 1, 2, 5
  • Healthcare workers and household contacts of high-risk individuals 1, 5, 7

Dosing Schedule

Most individuals require only ONE dose per influenza season. 8 The critical exception is children aged 6 months through 8 years receiving influenza vaccine for the first time or who received only one dose in previous seasons—these children require TWO doses administered ≥4 weeks apart. 1, 5, 8, 6

Specific Dosing by Age:

• Children 6-35 months: 0.25 mL or 0.5 mL (depending on product formulation) 3
• Children ≥36 months and adults: 0.5 mL 1, 3
• Two-dose requirement: Children <9 years who are vaccine-naïve or received only one prior dose need two doses ≥4 weeks apart; the second dose should ideally be administered before December 1, 5, 8
• Annual revaccination is mandatory because immunity declines within one year and viral strains change annually 1, 8

Critical Point on Repeat Dosing:

Administering multiple doses of the same seasonal vaccine formulation within a single season provides NO additional benefit and is NOT recommended, even in high-risk patients. 8 Studies show limited or no improvement in antibody response with repeat dosing during the same season. 1, 9

Administration Route

Influvac is administered via intramuscular (IM) injection. 1, 9

• Adults and older children: Deltoid muscle 9
• Infants and young children: Anterolateral aspect of the thigh 9
• Needle length: Use needles >1 inch for adults and older children to ensure adequate muscle penetration 9

Contraindications

Absolute contraindication: Anaphylactic hypersensitivity to eggs or other vaccine components 1

However, recent guidance has evolved: Persons with egg allergy of any severity may receive any licensed, age-appropriate influenza vaccine (including Influvac) without special precautions beyond those for any vaccine. 2 For those with severe egg allergy and high risk for influenza complications, appropriate allergy evaluation and desensitization may be considered. 1

Precautions (NOT absolute contraindications):

• Acute febrile illness: Defer vaccination until symptoms abate, though minor illnesses with or without fever do NOT contraindicate vaccination 1
• History of Guillain-Barré Syndrome (GBS): The risk of vaccine-associated GBS is estimated at 1-2 cases per 1 million vaccinees, which is substantially lower than the risk from influenza infection itself 10

Safety Profile

Influvac demonstrates an excellent safety profile established over 25 years of clinical use with 6,415 subjects studied. 11

Common Adverse Events (Mild-to-Moderate, Transient):

• Local reactions (most common): Pain, redness, or swelling at injection site affecting 10-64% of recipients, lasting <2 days 9, 12, 11
• Systemic reactions: Headache (16-44%), fatigue (25.7%), muscle aches, malaise, arthralgia 1, 12
• Fever: Occurs in 10-35% of children <2 years but rarely in older children and adults 13, 9
• Treatment-emergent adverse events: Occurred in only 13.7% of subjects in comprehensive safety analysis 11

Important Safety Considerations:

• Inactivated vaccines CANNOT cause influenza because they contain killed viruses 1, 9
• Serious adverse events: Occur at rates <1% in healthy children and adults 1
• Pregnancy safety: Vaccination during pregnancy is safe and provides protection to both mother and infant, with demonstrated efficacy in reducing laboratory-confirmed influenza in infants and febrile respiratory illness in mothers 12
• Febrile seizures: A slight increase was noted when administered concomitantly with 13-valent pneumococcal conjugate vaccine in young children during 2010-2012, but this should not preclude vaccination 13

Optimal Timing

Vaccination should ideally occur between September and November, with campaigns after mid-October preferred to ensure vaccine availability. 1, 9, 8, 6 However, vaccination should continue throughout the influenza season as long as viruses are circulating—late vaccination is better than no vaccination. 4, 8

Vaccine Effectiveness

Vaccine effectiveness varies by age, immune status, and match between vaccine and circulating strains:

• Well-matched seasons: 70-90% effectiveness in preventing laboratory-confirmed illness in healthy children and young adults 10, 14
• Suboptimal match: Effectiveness may be lower (e.g., 16% against A(H3N2) in 2021-22 season), but vaccine still prevents serious outcomes including hospitalization and death 15
• Mortality reduction: 65% effectiveness against influenza-associated death in children overall, 51% in children with underlying conditions 6
• Severe illness prevention: 75% reduction in life-threatening influenza illness in children 6
• Historical impact: Up to 80% of pediatric influenza deaths occur in unvaccinated or incompletely vaccinated children 6

Common Pitfalls to Avoid

• Do NOT delay vaccination waiting for a specific brand or "optimal timing"—any licensed, age-appropriate vaccine should be administered when available 8, 6
• Do NOT administer multiple doses of the same seasonal formulation within one season—this provides no benefit 8
• Do NOT use live attenuated vaccine (LAIV/FluMist) in patients with chronic medical conditions, immunosuppression, cardiovascular disease, or COPD—only inactivated vaccines like Influvac are appropriate 8, 6
• Do NOT assume prior vaccination provides multi-year protection—annual vaccination is mandatory due to antigenic drift and waning immunity 8
• Do NOT withhold vaccination from egg-allergic patients—current guidelines permit vaccination with appropriate monitoring 2